Chlorendic acid
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558612

CAS#: 115-28-6

Description: Chlorendic acid is a chemical intermediate used in the preparation of fire-retardant polyester resins and plasticizers.

Chemical Structure

img
Chlorendic acid
CAS# 115-28-6
Instruction

Theoretical Analysis

MedKoo Cat#: 558612
Name: Chlorendic acid
CAS#: 115-28-6
Chemical Formula: C9H4Cl6O4
Exact Mass: 385.82
Molecular Weight: 388.830
Elemental Analysis: C, 27.80; H, 1.04; Cl, 54.70; O, 16.46

Price and Availability

Size Price Availability Quantity
10g USD 285 2 Weeks
25g USD 500 2 Weeks
Bulk inquiry

Synonym: Chlorendic acid; Het acid; Kyselina het;

IUPAC/Chemical Name: 1,4,5,6,7,7-Hexachloro-8,9,10-trinorborn-5-ene-2,3-dicarboxylic acid

InChi Key: DJKGDNKYTKCJKD-UHFFFAOYSA-N

InChi Code: InChI=1S/C9H4Cl6O4/c10-3-4(11)8(13)2(6(18)19)1(5(16)17)7(3,12)9(8,14)15/h1-2H,(H,16,17)(H,18,19)

SMILES Code: O=C(C1C(C(O)=O)C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 388.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: National Toxicology Program. Chlorendic acid. Rep Carcinog. 2011;12:94-5. PubMed PMID: 21850124.

2: Decad GM, Fields MT. Disposition and excretion of chlorendic acid in Fischer 344 rats. J Toxicol Environ Health. 1982 May-Jun;9(5-6):911-20. PubMed PMID: 7120517.

3: Chlorendic acid. IARC Monogr Eval Carcinog Risks Hum. 1990;48:45-53. Review. PubMed PMID: 2197462.

4: National Toxicology Program . NTP Toxicology and Carcinogenesis Studies of Chlorendic Acid (CAS No. 115-28-6) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser. 1987 Apr;304:1-225. PubMed PMID: 12748725.

5: Chlorendic acid. Rep Carcinog. 2004;11:III50-1. PubMed PMID: 21089823.

6: Berger SA. Solvent extraction of copper(II) with chlorendic acid. Talanta. 1976 Jun;23(6):475-7. PubMed PMID: 18961903.

7: National Toxicology Program. Chlorendic acid. Rep Carcinog. 2002;10:50-1. Update in: Rep Carcinog. 2004;11:III50-1. PubMed PMID: 15318386.

8: Dragan YP, Rizvi T, Xu YH, Hully JR, Bawa N, Campbell HA, Maronpot RR, Pitot HC. An initiation-promotion assay in rat liver as a potential complement to the 2-year carcinogenesis bioassay. Fundam Appl Toxicol. 1991 Apr;16(3):525-47. PubMed PMID: 1855624.

9: Maronpot RR, Pitot HC, Peraino C. Use of rat liver altered focus models for testing chemicals that have completed two-year carcinogenicity studies. Toxicol Pathol. 1989;17(4 Pt 1):651-62. PubMed PMID: 2629100.

10: Guan M, Su G, Giesy JP, Zhang X. Classification and toxicity mechanisms of novel flame retardants (NFRs) based on whole genome expression profiling. Chemosphere. 2016 Feb;144:2150-7. doi: 10.1016/j.chemosphere.2015.10.114. Epub 2015 Nov 14. PubMed PMID: 26588597.

11: Kai G, Weber AS, Ying WC. Use of continuous-flow UV-induced mutation technique to enhance chlorinated organic biodegradation. J Ind Microbiol. 1991 Sep;8(2):99-106. PubMed PMID: 1367592.

12: Hasmall SC, Roberts RA. Hepatic ploidy, nuclearity, and distribution of DNA synthesis: a comparison of nongenotoxic hepatocarcinogens with noncarcinogenic liver mitogens. Toxicol Appl Pharmacol. 1997 Jun;144(2):287-93. PubMed PMID: 9194412.

13: Koufaris C, Wright J, Currie RA, Gooderham NJ. Hepatic microRNA profiles offer predictive and mechanistic insights after exposure to genotoxic and epigenetic hepatocarcinogens. Toxicol Sci. 2012 Aug;128(2):532-43. doi: 10.1093/toxsci/kfs170. Epub 2012 May 12. PubMed PMID: 22584684.

14: McGregor DB, Brown A, Cattanach P, Edwards I, McBride D, Caspary WJ. Responses of the L5178Y tk+/tk- mouse lymphoma cell forward mutation assay. II: 18 coded chemicals. Environ Mol Mutagen. 1988;11(1):91-118. PubMed PMID: 3338442.

15: Pitot HC, Campbell HA, Maronpot R, Bawa N, Rizvi TA, Xu YH, Sargent L, Dragan Y, Pyron M. Critical parameters in the quantitation of the stages of initiation, promotion, and progression in one model of hepatocarcinogenesis in the rat. Toxicol Pathol. 1989;17(4 Pt 1):594-611; discussion 611-2. Review. PubMed PMID: 2697939.

16: Matsuoka A, Yamakage K, Kusakabe H, Wakuri S, Asakura M, Noguchi T, Sugiyama T, Shimada H, Nakayama S, Kasahara Y, Takahashi Y, Miura KF, Hatanaka M, Ishidate M Jr, Morita T, Watanabe K, Hara M, Odawara K, Tanaka N, Hayashi M, Sofuni T. Re-evaluation of chromosomal aberration induction on nine mouse lymphoma assay "unique positive' NTP carcinogens. Mutat Res. 1996 Aug 12;369(3-4):243-52. PubMed PMID: 8792842.

17: Elcombe CR, Odum J, Foster JR, Stone S, Hasmall S, Soames AR, Kimber I, Ashby J. Prediction of rodent nongenotoxic carcinogenesis: evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotoxic NTP carcinogens. Environ Health Perspect. 2002 Apr;110(4):363-75. PubMed PMID: 11940454; PubMed Central PMCID: PMC1240799.

18: Neveu MJ, Hully JR, Paul DL, Pitot HC. Reversible alteration in the expression of the gap junctional protein connexin 32 during tumor promotion in rat liver and its role during cell proliferation. Cancer Commun. 1990;2(1):21-31. PubMed PMID: 1973356.

19: Sofuni T, Honma M, Hayashi M, Shimada H, Tanaka N, Wakuri S, Awogi T, Yamamoto KI, Nishi Y, Nakadate M. Detection of in vitro clastogens and spindle poisons by the mouse lymphoma assay using the microwell method: interim report of an international collaborative study. Mutagenesis. 1996 Jul;11(4):349-55. PubMed PMID: 8671759.

20: Hasmall SC, Pyrah IT, Soames AR, Roberts RA. Expression of the immediate-early genes, c-fos, c-jun, and c-myc: a comparison in rats of nongenotoxic hepatocarcinogens with noncarcinogenic liver mitogens. Fundam Appl Toxicol. 1997 Nov;40(1):129-37. PubMed PMID: 9398495.